Sampling Strategies for Tissue Microarrays to Evaluate Biomarkers in Ovarian Cancer

被引:11
作者
Permuth-Wey, Jenny
Boulware, David
Valkov, Nikola
Livingston, Sandra
Nicosia, Santo
Lee, Ji-Hyun
Sutphen, Rebecca
Schildkraut, Joellen [2 ]
Narod, Steven [3 ]
Parker, Alex [4 ]
Coppola, Domenico
Sellers, Thomas
Pal, Tuya [1 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Canc Epidemiol & Genet, MRC CANCONT, Tampa, FL 33612 USA
[2] Duke Univ, Durham, NC USA
[3] Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5S 1B2, Canada
[4] Mayo Clin, Coll Med, Jacksonville, FL 32224 USA
关键词
NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; MISMATCH-REPAIR; TUMOR HETEROGENEITY; BREAST-CANCER; RISK; IMMUNOHISTOCHEMISTRY; VALIDATION; CARCINOMA; HMLH1;
D O I
10.1158/1055-9965.EPI-08-0713
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Tissue microarrays (TMA) enable rapid analysis of biomarkers in large-scale studies involving archival tumor specimens, however, their utility in heterogeneous tumors such as ovarian cancer is limited. Methods: In this study, immunohistochemical analysis was done on TMAs comprised of epithelial ovarian cancer (EOC) to estimate the prevalence of loss of expression of three mismatch repair proteins. TMAs were initially created using cores sampled from the center of donor tissue blocks from 59 EOC cases. Full sections were subsequently created and levels of expression were compared between tissues sampled from the central portion versus the periphery. Followup analyses were done by obtaining cores from the periphery of up to five additional donor blocks per case. A linear mixed model for each protein was used to investigate differences between results from the initial and follow-up blocks. Results: In the original TMAs created using centrally sampled cores, loss of mismatch repair expression was noted in 17 (29%) of the 59 cases. By comparison, analyses from peripherally sampled cores revealed loss of expression in only 6 of these 17 cases. For each protein, significant differences (P < 0.05) were detected between results from the initial donor block and the majority of the follow-up blocks. Conclusions: Our investigations, based on EOC, suggest that sampling variability in protein expression may result when TMAs are used. Thus, at least for EOC, it is important to preferentially sample from the periphery of tumor blocks where exposure to tissue fixatives is optimal. (Cancer Epidemiol Biomarkers Prev 2009;18(1):28-34)
引用
收藏
页码:28 / 34
页数:7
相关论文
共 50 条
  • [41] Current state of biomarkers in ovarian cancer prognosis
    Au, Katrina K.
    Josahkian, Juliana A.
    Francis, Julie-Ann
    Squire, Jeremy A.
    Koti, Madhuri
    FUTURE ONCOLOGY, 2015, 11 (23) : 3187 - 3195
  • [42] Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays
    Jakobsson, Lovisa
    Chebil, Gunilla
    Marzouka, Nour-Al-Dain
    Liedberg, Fredrik
    Sjodahl, Gottfrid
    BLADDER CANCER, 2018, 4 (03) : 327 - 337
  • [43] A prototype for unsupervised analysis of tissue microarrays for cancer research and diagnostics
    Chen, WJ
    Reiss, M
    Foran, DJ
    IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE, 2004, 8 (02): : 89 - 96
  • [44] Therapeutic strategies in epithelial ovarian cancer
    Kim, Ayako
    Ueda, Yutaka
    Naka, Tetsuji
    Enomoto, Takayuki
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
  • [45] Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer
    Kobayashi, Eiji
    Ueda, Yutaka
    Matsuzaki, Shinya
    Yokoyama, Takuhei
    Kimura, Toshihiro
    Yoshino, Kiyoshi
    Fujita, Masami
    Kimura, Tadashi
    Enomoto, Takayuki
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (11) : 1902 - 1912
  • [46] Identification of biomarkers for cervical cancer in peripheral blood lymphocytes using oligonucleotide microarrays
    Sheng Jie
    Zhang Wei-yuan
    CHINESE MEDICAL JOURNAL, 2010, 123 (08) : 1000 - 1005
  • [47] Rapid Characterization of Candidate Biomarkers for Pancreatic Cancer Using Cell Microarrays (CMAs)
    Kim, Min-Sik
    Kuppireddy, Sarada V.
    Sakamuri, Sruthi
    Singal, Mukul
    Getnet, Derese
    Harsha, H. C.
    Goel, Renu
    Balakrishnan, Lavanya
    Jacob, Harrys K. C.
    Kashyap, Manoj K.
    Tankala, Shantal G.
    Maitra, Anirban
    Iacobuzio-Donahue, Christine A.
    Jaffee, Elizabeth
    Goggins, Michael G.
    Velculescu, Victor E.
    Hruban, Ralph H.
    Pandey, Akhilesh
    JOURNAL OF PROTEOME RESEARCH, 2012, 11 (11) : 5556 - 5563
  • [48] Combined use of biomarkers for detection of ovarian cancer in high-risk women
    Donach, Martin
    Yu, Yinhua
    Artioli, Grazia
    Banna, Giuseppe
    Feng, Weiwei
    Bast, Robert C., Jr.
    Zhang, Zhen
    Nicoletto, Maria O.
    TUMOR BIOLOGY, 2010, 31 (03) : 209 - 215
  • [49] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
    Hodgson, Darren R.
    Dougherty, Brian A.
    Lai, Zhongwu
    Fielding, Anitra
    Grinsted, Lynda
    Spencer, Stuart
    O'Connor, Mark J.
    Ho, Tony W.
    Robertson, Jane D.
    Lanchbury, Jerry S.
    Timms, Kirsten M.
    Gutin, Alexander
    Orr, Maria
    Jones, Helen
    Gilks, Blake
    Womack, Chris
    Gourley, Charlie
    Ledermann, Jonathan
    Barrett, J. Carl
    BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 1401 - 1409
  • [50] A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
    Terry, Kathryn L.
    Schock, Helena
    Fortner, Renee T.
    Huesing, Anika
    Fichorova, Raina N.
    Yamamoto, Hidemi S.
    Vitonis, Allison F.
    Johnson, Theron
    Overvad, Kim
    Tjonneland, Anne
    Boutron-Ruault, Marie-Christine
    Mesrine, Sylvie
    Severi, Gianluca
    Dossus, Laure
    Rinaldi, Sabina
    Boeing, Heiner
    Benetou, Vassiliki
    Lagiou, Pagona
    Trichopoulou, Antonia
    Krogh, Vittorio
    Kuhn, Elisabetta
    Panico, Salvatore
    Bueno-de-Mesquita, H. Bas
    Onland-Moret, N. Charlotte
    Peeters, Petra H.
    Gram, Inger Torhild
    Weiderpass, Elisabete
    Duell, Eric J.
    Sanchez, Maria-Jose
    Ardanaz, Eva
    Etxezarreta, Nerea
    Navarro, Carmen
    Idahl, Annika
    Lundin, Eva
    Jirstrom, Karin
    Manjer, Jonas
    Wareham, Nicholas J.
    Khaw, Kay-Tee
    Byrne, Karl Smith
    Travis, Ruth C.
    Gunter, Marc J.
    Merritt, Melissa A.
    Riboli, Elio
    Cramer, Daniel W.
    Kaaks, Rudolf
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4664 - 4675